Researchers sought to determine whether zanubrutinib combined with rituximab and lenalidomide would improve remission rates in older adults with newly diagnosed DLBCL.
For women with higher-risk breast cancer, 3 days of radiotherapy might enhance the immune response to checkpoint inhibitors.
The FDA cleared the investigational new drug (IND) application for a global phase 3 registrational trial of iSCIB1 +, a DNA plasmid vaccine, in patients with advanced melanoma, scheduled to commence ...
Greenwich's $3.81 million cash position covers less than two months of operations, making near-term financing highly likely ...
The financial trajectory of the exosome therapy market is decoupling from the broader, slower-growing regenerative medicine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results